Analyzing NGAL levels as a continuous variable in the adjusted-1 model revealed higher serum NGAL levels were significantly associated with increased risks of AMI (HR = 1.34, 95% CI = 1.12–1.59, p = 0.001), CV death (HR = 1.60, 95% CI = 1.32–1.95, p < 0.001), CHF (HR = 1.37, 95% CI = 1.17–1.61, p < 0.001), MACE (HR = 1.35, 95% CI = 1.18–1.54, p < 0.001), composite CV events (HR = 1.31, 95% CI = 1.17–1.48, p < 0.001), target vessel revascularization (HR = 1.35, 95% CI = 1.19–1.53, p < 0.001), and new-onset hemodialysis (HR = 1.47, 95% CI = 1.11–1.95, p = 0.007). Here, LCN2 is linked to congestive heart failure.